Manufacturer
GlaxoSmithKline
Contents
Predispensed umeclidinium 62.5 mcg, vilanterol (as trifenatate) 25 mcg. Delivered dose of umeclidinium 55 mcg, vilanterol (as trifenatate) 22 mcg
Indication
ANORO is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Instruction
Adult 1 inhalation once daily at the same time each day.
Drug interaction
Vilanterol: May weaken or antagonize effect w/ either nonselective or selective β-adrenergic blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors (eg, ketoconazole).